ストックスクリーナーアプリを入手
45.19
0.87%
0.39
前日終値:
$44.80
開ける：
$44.8
24時間の取引高:
5.40M
Relative Volume:
1.38
時価総額：
$19.36B
収益：
$2.35B
当期純損益:
$1.30B
株価収益率:
25.84
EPS:
1.7487
ネットキャッシュフロー:
$1.05B
1週間 パフォーマンス:
+1.21%
1か月 パフォーマンス:
+11.97%
6か月 パフォーマンス:
+23.94%
1年 パフォーマンス:
+39.22%
1日の値動き範囲:
$44.71
$45.91
1週間の範囲:
$42.50
$45.91
52週間の値動き範囲:
$29.66
$45.91
Royalty Pharma Plc Stock (RPRX) Company Profile
名前
Royalty Pharma Plc
セクター
電話
(212) 883-0200
住所
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.19 | 19.19B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-30 | アップグレード | UBS | Neutral → Buy |
| 2025-09-30 | 開始されました | Goldman | Buy |
| 2025-05-16 | 開始されました | Morgan Stanley | Overweight |
| 2024-06-03 | ダウングレード | UBS | Buy → Neutral |
| 2022-06-14 | 再開されました | UBS | Buy |
| 2022-05-13 | 開始されました | Scotiabank | Sector Outperform |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-14 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2021-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-07-30 | 開始されました | Tigress Financial | Buy |
| 2020-11-09 | アップグレード | UBS | Neutral → Buy |
| 2020-07-14 | 開始されました | Evercore ISI | In-line |
| 2020-07-13 | 開始されました | BofA Securities | Buy |
| 2020-07-13 | 開始されました | Citigroup | Neutral |
| 2020-07-13 | 開始されました | Cowen | Outperform |
| 2020-07-13 | 開始されました | Goldman | Neutral |
| 2020-07-13 | 開始されました | JP Morgan | Neutral |
| 2020-07-13 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 開始されました | SunTrust | Buy |
| 2020-07-13 | 開始されました | UBS | Neutral |
すべてを表示
Royalty Pharma Plc (RPRX) 最新ニュース
Envestnet Asset Management Inc. Purchases 339,839 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma: 2025 Financial Performance And Strategic Outlook - Seeking Alpha
(RPRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Quarterly Recap: Is Royalty Pharma plc stock undervalued right now2025 Stock Rankings & Smart Allocation Stock Tips - baoquankhu1.vn
Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend - Yahoo Finance
Activity Recap: Does IONS stock benefit from AI growthJuly 2025 Update & High Conviction Trade Alerts - baoquankhu1.vn
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions - MSN
Royalty Pharma Earnings Call Balances Strength And Risk - TipRanks
Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives - Sahm
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc stock see insider buyingMarket Weekly Review & Growth Focused Stock Reports - mfd.ru
Risks Report: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View (NASDAQ:RPRX) - Seeking Alpha
S P Trends: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Securities reiterates Buy rating on Royalty Pharma stock with $54 target - Investing.com Nigeria
BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma stock hits 52-week high at 44.94 USD By Investing.com - Investing.com Canada
Royalty Pharma's Disciplined Capital Allocation Approach and Appealing Market Growth Bolster Outlook - Morningstar
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - GuruFocus
Royalty Pharma Q4 2025 slides: double-digit growth amid synthetic royalty expansion - Investing.com Nigeria
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
Royalty Pharma earnings beat by $0.22, revenue fell short of estimates - Investing.com UK
Royalty Pharma plc (RPRX) Reports Q4 results - StreetInsider
Earnings Call Summary | Royalty Pharma(RPRX.US) Q4 2025 Earnings Conference - 富途牛牛
Royalty Pharma earnings beat by $0.22, revenue topped estimates - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235 - simplywall.st
Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase - MSN
Assessing Royalty Pharma (RPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Royalty Pharma stock hits 52-week high at 44.94 USD - Investing.com
Royalty Pharma (NASDAQ:RPRX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
RPRX: Double-digit growth, early capital deployment, and rising synthetic royalties drive strong outlook - TradingView
Earnings call transcript: Royalty Pharma beats Q4 2025 forecasts with strong EPS - Investing.com India
RPRX: Double-digit growth, early capital deployment, and strong 2026 outlook with cost savings - TradingView
Royalty Pharma Q4 Earnings Call Highlights - MarketBeat
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript - The Globe and Mail
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings - Yahoo Finance
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Royalty Pharma plc SEC 10-K Report - TradingView
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings - Finviz
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat - ChartMill
Royalty Pharma Reports Q4 and Full Year 2025 Results - TradingView
Royalty Pharma's Q4 Net Income, Revenue Rise - marketscreener.com
Earnings Flash (RPRX) Royalty Pharma Posts Q4 Net Income $356M - marketscreener.com
Royalty Pharma Plc (RPRX) 財務データ
収益
当期純利益
現金流量
EPS
1.12%
0.35%
大文字化:
|
ボリューム (24 時間):